NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
school
University Rankings
subject
University Subject Rankings
insights
Subject Rankings
place
Country Rankings
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Scott J Diede
Central US Merck & Co., Inc. - Kenilworth / United States
Others
AD Scientific Index ID: 4376442
-
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Scott J Diede's MOST POPULAR ARTICLES
1-)
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapyA Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ...Cell 170 (6), 1109-1119. e10, 201710222017
2-)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double …GV Long, R Dummer, O Hamid, TF Gajewski, C Caglevic, S Dalle, ...The Lancet Oncology 20 (8), 1083-1097, 20194812019
3-)
Telomerase-mediated telomere addition in vivo requires DNA primase and DNA polymerases α and δSJ Diede, DE GottschlingCell 99 (7), 723-733, 19994651999
4-)
Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaC Robert, A Ribas, O Hamid, A Daud, JD Wolchok, AM Joshua, WJ Hwu, ...Journal of clinical oncology 36 (17), 1668-1674, 20184532018
5-)
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trialJJ Luke, P Rutkowski, P Queirolo, M Del Vecchio, J Mackiewicz, ...The Lancet 399 (10336), 1718-1729, 20223552022
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept